°²öÎÓéÀÖ¹ÙÍø

³£¼ûÑÛ²¡ÐÂÎÅ

ÌÇÄò²¡ÊÓÍøĤ²¡±äµÄÒ½Öι²Ê¶

×÷ÕߣºÎ´Öª 2019-02-23 12:02:20
×ÖÌå´óС£º

¡¡¡¡ÌÇÄò²¡ÊÓÍøĤ²¡±ä(diabetic retinopathy£¬DR)Êdz£¼ûµÄÌÇÄò²¡ÂýÐÔ²¢·¢Ö¢Ö®Ò»£¬Ò²Êǵ¼Ö³ÉÈËʧÃ÷µÄÖ÷ÒªÔµ¹ÊÔ­ÓÉÖ®Ò»¡£DRÑÏÖØÍþв×ÅÌÇÄò²¡»¼ÕßµÄÉúÑÄÖÊÁ¿£¬Í¬Ê±¸øÉç»á´øÀ´ÑÏÖؾ­¼Ã¼ç¸º¡£

¡¡¡¡2014ÄêÖлªÒ½Ñ§»áÑÛ¿Æѧ·Ö»áÑ۵ײ¡Ñ§×éÐû²¼ÁË¡¶ÎÒ¹úÌÇÄò²¡ÊÓÍøĤ²¡±äÁÙ´²ÕïÁÆÖ¸ÄÏ¡·£¬Ö÷ÒªÓÃÒÔÖ¸µ¼È«¿Æҽʦ¡¢ÑÛ¿Æר¿ÆҽʦºÍÑ۵ײ¡ ҽʦ£¬¶øDRµÄɸ²é¡¢ÊÊʱתÕïºÍ·ÀÖÎÀë²»¿ªÄÚÉø͸¿ÆҽʦµÄ´¦Öóͷ££¬Òò´ËҲؽÐèÒ»·ÝÏìÓ¦µÄר¼Ò¹²Ê¶À´¹æ·¶ÁÙ´²ÕïÖΡ£Îª´Ë£¬ÖлªÒ½Ñ§»áÌÇÄò²¡Ñ§·Ö»áÊÓÍøĤ²¡±äѧ×é¡¢ÖйúҽʦЭ»áÕûºÏҽѧ·Ö»áÕûºÏÄÚÉø͸ÌÇÄò²¡Ñ§ ίԱ»áÔ¼ÇëÄÚÉø͸¡¢ÑۿƼ°Ïà¹Øר¼Ò£¬²Î¿¼Öйú2ÐÍÌÇÄò²¡·ÀÖÎÖ¸ÄÏ(2017Äê°æ)¡¢Öйú1ÐÍÌÇÄò²¡ÕïÖÎÖ¸ÄÏ(2011Äê°æ)ÒÔ¼°ÎÒ¹úºÍÎ÷Å·µÈ¹úDRÏà¹ØÁÙ´²ÕïÁÆÖ¸Äϼ°Ö÷ÒªµÄѭ֤ҽѧ֤¾Ý£¬ÒÔÖƶ©ÊʺÏÎÒº£ÄÚÉø͸ҽʦ²Î¿¼µÄDR·ÀÖÎר¼Ò¹²Ê¶¡£

¡¡¡¡Ò»¡¢DRµÄÊ¢ÐÐÇéÐÎDRÒò¹ú¼Ò¡¢µØÇø¡¢ÖÖ×å¶øÒ죬Éú³¤Öйú¼Ò½ÏÅ¹ú¼Ò»¼²¡ÂʵÍ¡£Ò»ÏîMetaÆÊÎöÄÉÈëÈ«Çò35ÏîÑо¿µÄ22 896 ÌÇÄò²¡»¼Õߣ¬Ð§¹ûÏÔʾDR»¼²¡ÂÊΪ34.6%£¬ÆäÖÐÔöÉúÐÍDR(proliferative diabetic retinopathy£¬PDR)Ϊ6.96%£¬ÌÇÄò²¡ÐԻưßË®Ö×(diabetic macular edema£¬DME)Ϊ6.81%£¬ÍþвÊÓÁ¦µÄDRΪ10.2%¡£À´×ÔÎÒ¹úµÄÑо¿ÏÔʾ£¬Öйú´ó½ÌÇÄò²¡ÈËȺDR»¼²¡ÂÊΪ23%(95%CI: 17.8%~29.2%)£¬ÆäÖзÇPDR(nonproliferative diabetic retinopathy£¬NPDR)Ϊ19.1%(13.6%~26.3%)£¬PDRΪ2.8%(1.9%~4.2%)£¬Å©´å¸ßÓÚ¶¼»á£¬±±·½¸ßÓÚÄÏ·½ºÍ¶«²¿¡£Ð¼ÓÆ»ªÈËÖÐÌÇÄò²¡ÈËȺDR»¼²¡ÂÊΪ20.1%£¬ÃÀ¹ú»ªÈËÖÐÌÇÄò²¡ÈËȺDR»¼²¡ÂÊΪ25.7%[10]¡£¶øÎÒ¹ų́ÍåµØÇøDR»¼²¡ÂÊΪ35%£¬Ïã¸ÛµØÇøµÄ»¼²¡ÂÊΪ18.2%¡£

¡¡¡¡¶þ¡¢DRµÄΣÏÕÒòËØDRµÄÖ÷ҪΣÏÕÒòËØ°üÀ¨¸ßѪÌÇ»òÏÔ×ÅѪÌDz¨¶¯¡¢¸ßѪѹ¡¢¸ßѪ֬¡¢ÌÇÄò²¡²¡³Ì³¤¡¢ÌÇÄò²¡Éö²¡(DKD)¡¢ÈÑÉï¡¢·ÊÅÖ¡¢Ò׸лùÒòµÈ(±í1)[13,14]¡£ÖйúÈËȺÖУ¬ÒÑ֤ʵµÄDRÒ׸лùÒò°üÀ¨CPVL/CHN2¡¢SCAF8-CNKSR3¡¢SCYL1BP1¡¢API5¡¢CRPºÍFNDC5µÈ[15,16,17,18,19]¡£ÎÒ¹ų́ÍåÈËȺµÄDRÈ«»ùÒò×é¹ØÁªÆÊÎöÌáÐÑ5¸öȾɫÌåÒ׸ÐÇøÓòºÍº¬PLXDC2¡¢RhoARHGAP22µÄ»ùÒòÓëDRÏà¹Ø£¬ºóÁ½¸ö»ùÒò¼ÓÈëÄÚƤϸ°ûѪ¹ÜÌìÉú²¢¸Ä±äëϸѪ¹Üͨ͸ÐÔ[20]¡£ºº×åÈËȺÑо¿ÌáÐÑȾɫÌå13q22.2¡¢2q31.1ºÍ2q37.2±£´æ3¸öDZÔÚÒ׸Ðλµã¡£

¡¡¡¡Ñо¿ÌáÐÑÒȵºËضԿ¹ÎªDRÏ£ÍûµÄΣÏÕÒòËØ£¬ÇÒ×ÔÁ¦ÓÚÆäËû´úлΣÏÕÒòËØ¡£Òȵº¦Âϸ°ûÉø͸ÒȵºËØÄÜÁ¦Ï½µÒ²ÊÇÑÏÖØDRµÄΣÏÕÒòËØ¡£ÆäËûÏà¹ØΣÏÕÒòËØ°üÀ¨ÎüÑÌ¡¢ÑÇÁÙ´²¼××´ÏÙ¹¦Ð§¼õµÍ¡¢Ë¯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢ÑªÇåÃÚÈéËØ¡¢Ö¬ÁªËؼ°Í¬ÐÍ°ëë×°±ËáˮһÂÉ¡£

·µ»Ø ÔÚÏß×Éѯ
ÍøÕ¾µØͼ